Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.

ABSTRACT: Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed promising efficacy against gastric cancer (GC) in a preclinical study. Here we report the interim analysis results of an ongoing, open-label, single-arm, phase 1 clinical trial of CLDN18.2-targeted CAR T cells (CT041) in patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897 ). The primary objective was safety after CT041 infusion; secondary objectives included CT041 efficacy, pharmacokinetics and immunogenicity. We treated 37 patients with one of three CT041 doses: 2.5 × 10⁸, 3.75 × 10⁸ or 5.0 × 10⁸ cells. All patients

SUBMITTER: Qi C 

PROVIDER: S-EPMC9205778 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature